Trial · NCT00790803
Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema
NCT00790803, Not applicable, Completed, Wake Forest University; results first posted 2013-09-26
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema. Trials, record NCT00790803. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00790803
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema
- NCT number
- NCT00790803
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 5 participants, actual
- Lead sponsor
- Wake Forest University
- Conditions
- Uveitis, Cystoid Macular Edema
- Interventions
- Pegaptanib
- First posted
- 2008-11-14
- Last updated
- 2022-03-15
- Results first posted
- 2013-09-26
- Limitations and caveats
- Implementing screening protocols to catch less progressed CME cases could improve outcomes.
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Improvement in VA ETDRS >/= 15 Letters | 32 weeks | The primary outcome was an improvement in VA greater than or equal to fifteen letters on the EDTRS chart. |
| Secondary | Proportion of Patients Experiencing > 0 Letter Vision Gain and a < 15 Loss | 32 weeks | Patients best corrected visual acuity was measured at each visit to monitor gain or loss of letters on the EDTRS chart. |
| Secondary | Decrease in CME as Evidenced by Imaging (Fluorescein Angiography and 50 Micron Change in OCT) | 32 weeks | Patients retinal thickness was measured at each visit bu imaging to monitor increase or decrease in thickness. |
| Secondary | A Decrease in Anterior Chamber Cells or Vitreous Cells or Haze in Injected Eye | 32 weeks | The degree of cell and flare was recorded at each visit during the course of the trial in the injected eye. In uveitis, severely inflamed vessels leak protein which clouds the normally clear aqueous. This looks hazy with the slit lamp. If severe, it disperses the light beam, causing flare. White or red blood cells may be observed: the presence of inflammatory cells in the anterior chamber suggests inflammation of the iris and ciliary body. Blood cells: grading of blood cells in the anterior chamber is as follows: * 0 - None. * 1+ - faint (barely detectable). * 2+ - moderate (clear iris and lens details). * 3+ - moderate (hazy iris and lens details). * 4+ - intense (fibrin deposits, coagulated aqueous). |
| Secondary | Change in Immunomodulatory Medications (Topical, Periocular or Systemic) After the Initiation of Macugen Therapy | 32 weeks | No changes were to be made in immunodulatory medications of the patients unless needed for safety after in initiation of Macugen therapy. |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Improvement in VA ETDRS >/= 15 Letters | 32 weeks | Five consecutive adult patients with non-infectious uveitis associated CME were chosen from the PI's regular medical clinic. Patients demonstrated, on fluorescein angiogram and/or optical tomography, bilateral or unilateral CME with non-infectious uveitis for greater than three months, but less than twelve. | participants | NUMBER |
| SECONDARY | Proportion of Patients Experiencing > 0 Letter Vision Gain and a < 15 Loss | 32 weeks | paticipants | NUMBER | |
| SECONDARY | Decrease in CME as Evidenced by Imaging (Fluorescein Angiography and 50 Micron Change in OCT) | 32 weeks | participants | NUMBER | |
| SECONDARY | A Decrease in Anterior Chamber Cells or Vitreous Cells or Haze in Injected Eye | 32 weeks | participants | NUMBER | |
| SECONDARY | Change in Immunomodulatory Medications (Topical, Periocular or Systemic) After the Initiation of Macugen Therapy | 32 weeks | participants | NUMBER |
Source ClinicalTrials.gov
Results by group5
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Improvement in VA ETDRS >/= 15 Letters | Macugen | 1 | participants | ||
| Proportion of Patients Experiencing > 0 Letter Vision Gain and a < 15 Loss | Macugen | 5 | paticipants | ||
| Decrease in CME as Evidenced by Imaging (Fluorescein Angiography and 50 Micron Change in OCT) | Macugen | 2 | participants | ||
| A Decrease in Anterior Chamber Cells or Vitreous Cells or Haze in Injected Eye | Macugen | 0 | participants | ||
| Change in Immunomodulatory Medications (Topical, Periocular or Systemic) After the Initiation of Macugen Therapy | Macugen | 0 | participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Macugen | 5 | |
| Overall Study | COMPLETED | Macugen | 5 | |
| Overall Study | NOT COMPLETED | Macugen | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Macugen | ||
| Total, other adverse events | Macugen | 0 | 5 |
| Total, serious adverse events | Macugen | 0 | 5 |
Source ClinicalTrials.gov
Papers14
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00790803
GET https://conductscience.org/api/trials/v1/NCT00790803/registered